Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label randomised multicenter clinical study to compare immunogenicity of the
drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes
mellitus patients